序号股票简称PE(TTM)PE(静)市净率总市值(元)121赛诺医疗2465.352465.354.3737.50亿行业平均 45.9448.384.71101.41亿行业中值29.6428.792.3545.52亿1天益医疗-2672.56-2672.561.6719.88亿2硕世生 物-1835.15-1835.151.1537.91亿3诺唯赞-549.11-549.112.5299.35亿4博晖创新-335.30-206.443.6951.46亿5康 泰医学-262.5830.812.6851.07亿6华大基因-197.28215.792.04200.47亿7奥精医疗-108.26-108.261.3819.61亿 8睿昂基因-79.59-79.591.2411.51亿9热景生物-60.65-60.653.33108.69亿10华大智造-52.74-52.743.96315.97 亿11中红医疗-48.32-32.870.7743.02亿 来源：金融界 4月16日，赛诺医疗今日收盘9.07元，下跌3.41%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到2465.35倍，总市值37.50亿 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Sino Medical, indicating a significant disparity between its high PE ratio and the industry average [1][2] - As of April 10, Sino Medical's closing price was 9.21 yuan, with a PE ratio of 2503.41, significantly higher than the industry average of 46.15 [1][2] - The company's total market capitalization stands at 3.808 billion yuan, ranking it 121st in the medical device industry [1][2] Group 2 - Sino Medical specializes in the research, production, and sales of high-end interventional medical devices, with its main products being coronary stent systems and balloon dilation catheters [1] - The latest financial report for Q3 2024 shows a revenue of 318 million yuan, representing a year-on-year increase of 30.20%, while the net profit was a loss of approximately 6.74 million yuan, a year-on-year decline of 83.84% [1] - The gross profit margin for the company is reported at 61.29% [1]